Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$64.20T
24h Vol:
$8.52B
Dominance:
MSFT:4.79%
Stocklytics Platform
Instrument logo  DNA
Ginkgo Bioworks Holdings
DNA
55 / 100
$0.76arrow_drop_down17.28%-$0.15

Performance History

Stocklytics logo
Key Stats
Open$0.79
Prev. Close$0.92
EPS-0.46
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap1967990528.00
PE Ratio-
LOWHIGH
Day Range0.72
0.82
52 Week Range0.72
2.54
Ratios
P/B Ratio1.98
Revenue$251.45M
Operating M. %-515.53%
Earnings$0.00
Earnings Growth %57.61%
EBITDA Margin %-263.38%
ROE %-63.02%
EPS-0.46

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

55vs 56. Market Avg.

All Score 55 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

DNAMARKET
Value4838
Quality4240
Ownership3617
Growth4646
Dividends-37
check_circle

Ginkgo Bioworks Holdings's Price discount from 1 year high of 61.74% is great compared to market average of 16.77%. This indicates DNA could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$760.00
24H (%)arrow_drop_down1.49%
24H ($)-$11.54
MARKET CAP$739.19B
PRICE$512.81
24H (%)arrow_drop_up1.13%
24H ($)$5.78
MARKET CAP$453.09B
PRICE$149.91
24H (%)arrow_drop_up0.04%
24H ($)$0.06
MARKET CAP$357.92B
PRICE$130.06
24H (%)arrow_drop_down0.13%
24H ($)-$0.17
MARKET CAP$322.98B

About Ginkgo Bioworks Holdings (DNA)

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jason Kelly
Headquarters
Boston
Employees
1292
Exchange
NYSE
add Ginkgo Bioworks Holdings to watchlist

Keep an eye on Ginkgo Bioworks Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Ginkgo Bioworks Holdings's (DNA) price per share?

The current price per share for Ginkgo Bioworks Holdings (DNA) is $0.76. The stock has seen a price change of -$0.16 recently, indicating a -17.28% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Ginkgo Bioworks Holdings (DNA)?

For Ginkgo Bioworks Holdings (DNA), the 52-week high is $2.54, which is 234.43% from the current price. The 52-week low is $0.72, the current price is 5.69% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Ginkgo Bioworks Holdings (DNA) a growth stock?

Ginkgo Bioworks Holdings (DNA) has shown an average price growth of 0.41% over the past three years. It has received a score of 5 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Ginkgo Bioworks Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Ginkgo Bioworks Holdings (DNA) stock price performance year to date (YTD)?

As of the latest data, Ginkgo Bioworks Holdings (DNA) has a year-to-date price change of -54.43%. Over the past month, the stock has experienced a price change of -32.05%. Over the last three months, the change has been -49.6%. Over the past six months, the figure is -40.55%.

help
Is Ginkgo Bioworks Holdings (DNA) a profitable company?

Ginkgo Bioworks Holdings (DNA) has a net income of -$892.87M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 56.73% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -515.53% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $251.46M, although specific revenue growth data is currently not available. The gross profit is $142.64M. Operating income is noted at -$672.23M. Furthermore, the EBITDA is -$662.28M.

help
What is the market capitalization of Ginkgo Bioworks Holdings (DNA)?

Ginkgo Bioworks Holdings (DNA) has a market capitalization of $1.97B. The average daily trading volume is 64.14M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.